#ASGCT26: A Zillow-Like Marketplace for Abandoned Gene Therapies Goes Live

Why It Matters

By creating a transparent hub for orphaned therapies, the marketplace reduces wasted R&D spend and accelerates the delivery of potentially life‑saving treatments to rare‑disease populations.

Key Takeaways

• ASGCT and Orphan Therapeutics launched a marketplace for unused gene therapies
• Platform lists over 30 abandoned cell and gene therapy candidates
• Matches therapies with biotech firms, investors, and academic partners for redevelopment
• Aims to cut pipeline attrition and speed rare‑disease treatments

Pulse Analysis

The biotech sector has long struggled with a high attrition rate for cell and gene therapies, often leaving promising candidates on the shelf after early‑stage setbacks. These abandoned assets represent years of scientific work and substantial sunk costs, yet they rarely find a new sponsor because data are fragmented and potential buyers lack visibility. A dedicated marketplace addresses this gap by consolidating information, standardizing data formats, and offering a searchable interface that mirrors real‑estate platforms like Zillow, making it easier for stakeholders to discover and evaluate dormant projects.

The new ASGCT‑Orphan Therapeutics platform functions as a digital broker, cataloguing each therapy’s mechanism of action, pre‑clinical results, regulatory status, and intellectual property position. Users can filter by disease indication, vector type, or development stage, then initiate contact with the current holder—often a university or small biotech—that retains the rights. By streamlining due diligence and reducing transaction friction, the marketplace lowers the barrier for mid‑size companies and venture capital firms to acquire or co‑develop assets that would otherwise be lost, fostering a more efficient pipeline for rare‑disease interventions.

Industry analysts anticipate that this transparency will spur a modest but meaningful increase in repurposing deals, potentially unlocking billions of dollars in previously stranded R&D investment. For patients with ultra‑rare conditions, faster access to advanced therapies could translate into earlier clinical trials and, ultimately, approved treatments. Moreover, the model may inspire similar initiatives across other high‑cost therapeutic areas, reinforcing a collaborative ecosystem that balances scientific ambition with commercial viability.